Scholar Rock has announced positive results from its Phase 3 clinical trial evaluating apitegromab in patients with spinal muscular atrophy (SMA). The study, which assessed the drug's efficacy on top of existing SMA treatments, revealed statistically significant improvements in motor function among treated patients, potentially paving the way for its approval.
The Phase 3 trial focused on children aged 2 to 12, a key demographic affected by SMA. Patients receiving apitegromab demonstrated a 1.8-point greater improvement on the Hammersmith Functional Motor Scale compared to the placebo group. This primary endpoint suggests a clinically meaningful benefit in motor skills and overall functionality.
Further analysis of the data revealed that 30% of patients treated with apitegromab experienced a greater than 3-point improvement on the motor scale, compared to only 12.5% of patients in the placebo group. This highlights the potential of apitegromab to provide substantial benefits for a significant proportion of SMA patients.
Notably, improvements in motor function were observed as early as eight weeks after treatment initiation, with the benefits continuing to expand over the one-year duration of the study. This early and sustained response suggests that apitegromab could offer a valuable therapeutic option for managing SMA and improving patient outcomes.
The successful Phase 3 trial results position apitegromab as a promising new treatment for spinal muscular atrophy, offering hope for improved motor function and quality of life for affected individuals.
